Latest News and Press Releases

Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies...

Rehovot, Israel, March 02, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies...

REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune...

Virtual Bell-Ringing Ceremony in Celebration of Company’s Recent Name Change to Purple Biotech REHOVOT, Israel, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”)...

New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: KTOV),...

TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...

TEL AVIV, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...

Patent covers NT219’s combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®) TEL AVIV, Israel, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma...

Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance TEL AVIV, Israel, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage...

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...